Tarsus Pharmaceuticals (NASDAQ:TARS) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS - Free Report) in a report released on Monday. The firm issued an outperform rating and a $75.00 price objective on the stock.

A number of other equities analysts have also issued reports on the stock. The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research report on Thursday, March 6th. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price target on the stock in a report on Tuesday, May 27th. Finally, Barclays lowered their price target on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $66.67.

Tarsus Pharmaceuticals Stock Performance

TARS stock traded up $0.06 on Monday, reaching $43.91. 261,524 shares of the company were exchanged, compared to its average volume of 701,228. Tarsus Pharmaceuticals has a 12 month low of $20.08 and a 12 month high of $57.28. The stock's fifty day moving average price is $46.79 and its 200 day moving average price is $48.95. The firm has a market capitalization of $1.84 billion, a PE ratio of -11.52 and a beta of 0.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The business had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. On average, research analysts anticipate that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the company's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 824,106 shares of the company's stock, valued at approximately $41,205,300. This represents a 0.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Dianne C. Whitfield sold 2,137 shares of the company's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $107,085.07. Following the completion of the sale, the insider now directly owns 46,355 shares in the company, valued at approximately $2,322,849.05. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Large investors have recently made changes to their positions in the company. Crowley Wealth Management Inc. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $25,000. GF Fund Management CO. LTD. acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $44,000. Amalgamated Bank lifted its position in Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after buying an additional 295 shares in the last quarter. Quarry LP acquired a new position in Tarsus Pharmaceuticals during the 4th quarter worth about $166,000. Finally, AlphaQuest LLC acquired a new position in Tarsus Pharmaceuticals during the 1st quarter worth about $189,000. Institutional investors own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.